Volume 4, Abstract Book BHS, January 2013

Index

ABSTRACTS (e-)POSTER PRESENTATIONS

P.42 Microvesicles bearing Tissue-Factor: a new potential biomarker for thrombosis in acute promyelocytic leukaemia

D. Gheldof


P.43 Pneumatosis intestinalis as a sign of acute graft versus host disease. Pneumatosis intestinalis as a sign of acute graft versus host disease

M. Vekemans, Y.E. El Hassouni, V.H. Havelange, A. Devresse, B. Doyen, L. Michaux, E. Danse, E. Van den Neste, X. Poiré


P.44 Localised leukaemic cerebral relapse following zygomycosis of the ear after chemotherapy consolidation for AML M1

F. Aboubakar, L. Michaux, J.C. Yombi, E. Van den Neste, A. Ferrant, M-C. Vekemans


P.45 Cerebrospinal fluid invasion in an APL patient. A case report

L. Plawny, A.V. Schettini


P.46 Purple skin lesions and low back pain

F. Aboubakar, S. Hardy, D. Manicourt, B. Vande Berg, J.M. Scheiff, L. Michaux, M-C. Vekemans


P.47 Impact of the oral and direct Factor Xa inhibitor Rivaroxaban on five routine coagulation assays, an in-vitro and ex-vivo study

L. Dierge, E. Fosse, A. Alewaeters, D. Govaerts, P. Cauchie


P.49 Impact of thromboplastin’s choice on VKA treated patients monitoring

P. Cauchie, P. Boursin, N. Deschepper, N. Barat, A. Alewaeters, N. Thuillier


P.50 Rituximab as a maintenance treatment in thrombotic thrombocytopenic purpura : a case report

N. Baicu, L. Plawny


P.51 Relationship between thrombin generation and blood flow velocity in large cerebral arteries of children with sickle cell disease

D. Noubouossie, F. Ziereisen, P.-Q. Le, D. Willems, B. Mahadeb, L. Rozen, M. Ngalula Mujinga, A. Demulder, A. Ferster


P.52 Newborn screening for Sickle Cell Disease in Brussels, a program with an ongoing clinical outcome improvement

P.-Q. Le, B. Gulbis, L. Dedeken, C. Heijmans, A. Vanderfaeillie, C. Vermylen, S. Huybrechts, C. Devalck, F. Cotton, B.C. Nguyen, F. Vertongen, M. Ngalula, A. Ferster


P.52 Neuropeptides to replace serum in cryopreservation of mesenchymal stem cells?

A. Briquet, A. Halleux, C. Lechanteur, Y. Beguin


P.53 Acute liver failure in a patient with sickle/ beta-thalassemia (S/β)

F. Van Obbergh, C. Lambert, O. Ciccarelli, C. Dangoisse, C. Sempoux, L. Knoops, A. Ferrant, L. Michaux, M-C. Vekemans


P.54 Establishment of transgenic human embryonic stem cell lines for the study of human hematopoiesis

S. Vanhee, K. De Mulder, Y. Van Caeneghem, I. Velghe, S. Snauwaert, G. Verstichel, G. Goetgeluk, T. Kerre, B. Vandekerckhove


P.55 Expression of the hemogenic transcription factor Runx1 in in vitro generated hematopoietic progenitor cells

Y. Van Caeneghem, S. Vanhee, K. De Mulder, I. Velghe, S. Snauwaert, G. Verstichel, G. Goetgeluk, T. Kerre, B. Vandekerckhove


P.56 Serum hepcidin following autologous haematopoietic cell transplantation : an illustration of the interplay of erythropoiesis, iron status and inflammation

A. Jaspers, F. Baron, E. Willems, E. Wiegerinck, D. Swinkels, Y. Beguin


P.58 Impacts of the JACIE accreditation at the department of Hematology at Jules Bordet Institute (IJB) and the Hemato-Oncology Service of Hopital Universitaire Des Enfants Reine Fabiola (HUDERF)

P.H. Huynh, O.Urbain, R.Leroy, P.Crombez, Ph. Lewalle, N. Meuleman, A. Delforge, S.Michiels, M-F.J


P.59 Protective Isolation in Hematology : Risk Assessment and Environmental Control

M. Bourgeois, A. Sonet, C. Graux, C. Chatelain, C. Doyen, C. Baiana, C. Crivisqui, Y. Glupczynski, M. André


P.60 Haematopoietic stem cell transplantation in a patient with WHIM syndrome and pancytopenia: status at +1y

I. Meyts, D. Blockmans, F. Temmerman, X. Bossuyt, G. Diaz, M. Slatter, D. Dierckx


P.61 Graft-versus-host disease is a rare and tricky complication after autologous haematopoietic stem cell transplantation

M. Berckmans, M. Laruelle, X. Poiré, V. Havelange, M-C. Vekemans, L. Michaux, E. Van den Neste


P.62 Isolated sphenoid fungal sinusitis as a rare cause of vision loss in a patient undergoing stem cell transplantation

B. Hodossy, S. Helsen, A. Verlinden, A. Van de Velde, A. Gadisseur, W. Schroyens, Z. Berneman, I. Vrelust


P.63 Successful treatment of late recurrence of mucormycosis with atypical presentation after haematopoietic stem cell transplantation

D. Mazure, L. Noens, T. Kerre


P.64 MicroRNA profile of circulating CD4-positive regulatory T cells in human adults and the impact of differentially expressed microRNAs on the expression of two genes essential to their function

H. Fayyad Kazan, R. Rouas, P. Lewalle, F. Jebbawi, M. Merimi, A. Burny, B. Badran, P. Martiat


P.65 Human natural CD8-positive Treg microRNA signature: effect on regulatory T cell associated-genes

R. Rouas, F. Jebbawi, H. Fayyad Kazan, M. Merimi, P. Lewalle, B. Badran, P. Martiat


P.66 TCR-dependency of T cell maturation in OP9-DL1 cocultures

G. Verstichel, S. Snauwaert, S. Vanhee, Y. Van Caeneghem, K. Demulder, I. Velghe, G. Goetgeluk, T. Kerre, B. Vandekerckhove


P.67 Comparison of immune reconstitution after hematopoietic stem cell transplantation with FLU-TBI vs. TLI-ATG conditioning

M. Hannon, S. Humblet-Baron, C. Graux, J. Maertens, T. Kerre, K. Theunissen, C. Daulne, E. Willems, L. Belle, M. Binsfeld, A. Gothot, Y. Beguin, F. Baron


P.68 Heterosexual HIV-1 Transmission is Associated with Allogeneic KIR/HLA Ligand Combinations Governing Natural Killer Cell Alloreactivity

W. Jennes, S. Verheyden, C. Demanet, J.W. Mertens, C. Camara, M. Seydi, T. Dieye, S. Mboup, L. Kestens


P.69 Identification of biomarkers of hemostatic, endothelial and immune function in sepsis

A. Gothot, C. Gosset, J. Foguenne, C. Lecut, P. Damas, C. Oury, P. Massion


P.70 Immune Reconstitution After Alternative Hematopoietic Stem Cell Transplantation: Comparison of Unrelated Cord Blood (CB) and Mismatched Unrelated Donor (mmUD) Stem Cell Transplantation (SCT)

S. Servais, C. Granier, M. Robin, A. Xhaard, R. Peffault de Latour, G. Socie


P.71 Swachman-Diamond Syndrome: Frequent misdiagnosis as Jeune Syndrome and other peculiarities

I. Meyts, H. Schaballie, F. Haerynck, L. Sevenants, C. Vermylen, V. Bordon, X. Bossuyt, A. Corveleyn, A. Uyttebroeck, M. Renard


P.72 Successful Autologous Stem Cell Transplantation in a Girl with Neuropsychiatric Systemic Lupus Erythematosus

V. Bordon, P. Verloo, S. Verbeek, C. Dhooge


P.73 The immunomodulating peptide thymosin alpha 1 has no effects on multiple myeloma evolution and on immune reconstitution

M. Binsfeld, E. Otjacques, M. Hannon, S. Dubois, Y. Beguin, F. Baron, J. Caers


P.74 Rothmund-Thomson Syndrome: Immuno-Osseous challenges

I. Meyts, L. de Somer, X. Bossuyt, M. Morren, K. Devriendt, C. Wouters


P.75 Invasive Aspergillus pneumonitis as a first presentation of X-linked Chronic Granulomatous Disease (X-CGD)

I. Meyts, T. van Ackere, A. Allemon, M. Proesmans, A.M. Rentmeesters


P.76 A 10-year single center study of adult patients with histiocytic disorders in Antwerp

A. Van de Velde, E. Vermander, I. Vrelust, I. Vandenbosch, A. Gadisseur, W. Schroyens, Z.N. Berneman


P.01 NUP214-ABL1 mediated cell proliferation in T-ALL depends on the LCK kinase and various interacting proteins

K. De Keersmaecker, M. Porcu, L. Cox, R. Vandepoel, T. Girardi, O. Gielen, N. Mentens, K.L. Bennett, O. Hantschel, J. Cools


P.02 H3K27me3 erasers, novel targets in T-cell acute lymphoblastic leukaemia

J. Van der Meulen, K. Mavrakis, V. Sanghvi, B. Poppe, N. Van Roy, P. Rondou, Y Benoit, P. Van Vlierberghe, H. Wendel, F. Speleman


P.03 Extending the functional redundant cooperative miRNA tumour suppressor and oncogene network in T-ALL

E. Mets, G. van Peer, J. Van der Meulen, P. Mestdagh, T. Taghon, D. Avran, Y Benoit, B. Poppe, J. Soulier, P. Van Vlierberghe, P. Rondou, J. Vandesompele, F. Speleman


P.04 HDAC in Chronic Lymphocytic Leukaemia: expression profile, enzymatic activity and prognostic significance

M. Van Damme, E. Crompot, N. Meuleman, P. Mineur, D. Bron, L. Lagneaux, B. Stamatopoulos


P.05 The Combination of Decitabine and the Histone Deacetylase Inhibitor JNJ-26481585 Has Synergistic Anti-Myeloma Activity

K. Maes, M. Lemaire, E. De Smedt, E. Menu, E. Van Valckenborgh, K. Vanderkerken, E. De Bruyne


P.06 Safety and efficacy of abbreviated induction with oral fludarabine (F) and cyclophosphamide (C) combined with dose-dense iv rituximab (R) in previously untreated patients with chronic lymphocytic leukaemia (CLL) aged > 65 years: results of a multicentre trial (LLC 2007 SA) on behalf of the French

W. van den Neste, C. Dartigeas, C. Berthou, H. Maisonneuve, S. Leprêtre, M.S. Dilhuydy, M.C. Béné, F. Nguyen-Khac, R. Letestu, F. Cymbalista, S. de Guibert, T. Aurran, K. Laribi, J.P. Vilque, O. Tournilhac, A. Delmer, P. Feugier, B. Cazin, A.S. Michallet, V. Lévy, X. Troussard, R. Delepine, B. Giraudeau, P. Colombat, V. Leblond


P.07 Interim analysis of the randomized EORTC/ LYSA/FIL Intergroup H10 trial on early PET-scan driven treatment adaptation in stage I/II Hodgkin lymphoma

P. André, E. Van den Neste, G. Verhoef, D. Bron, A. Van Hoof, P. Zachée, S. van Steenwegen, B. De Prijck, N. Straetmans, M. Maerevoet, D. Boulet, F. Offner, P. Pierre, V. Mathieux, P. Mineur, T. Connerotte, M. Federico, J. Raemaekers


P.08 Comparison of Long-Term Outcome between Belgian and Vietnamese Children Treated for Acute Lymphoblastic Leukaemia according to Fralle 2000 protocol

P. Vu Hoang, J. Ambroise, V.L. Dang Chi, A.F. Dekairelle, S. Dupont, N. Huynh, T.B. Nguyen, J.L. Gala, C. Vermylen


P.09 Exome sequencing identifies mutation of CNOT3 in T-cell acute lymphoblastic leukaemia

C. Vicente, K. De Keersmaecker, Z. Kalender Atak, J. Yan, N. Li, V. Gianfelici, E. Geerdens, E. Clappier, G. Hulselmans, R. Vande poel, B. Cauwelier, J. Cloos, J. Soulier, A. Uyttebroeck, B. Hassan, P. Vandenberghe, S. Aerts, J. Cools


P.10 Role of HH pathway in T cell acute lymphoblastic leukaemia (T-ALL)

A. Dagklis, D. Pauwels, I. Lahortiga, Z.K. Atak, K. De Keersmaecker, K. Jacobs, N. Mentens, A. Uyttebroeck, J. Maertens, G. Verhoef, S. Aerts, P. Vandenberghe, J. Cools


P.11 Expression of ZAP-70 in CLL activates NF-?B signaling

V. Pede, R. A. Rombout, V. J. Vermeire, N. E. Naessens, V. H. Vanderstraeten, P. J. Philippé, V. B. Verhasselt


P.12 Evaluation of CD200 expression in differential diagnosis of CD5+ B cell NHLs

B.A.P.M. Depreter, J. Emmerechts, B. Cauwelier


P.13 G8 as a screening tool for older patients with malignant haemopathies: A surrogate for CGA?

S. Dubruille, M. Maerevoet, R. Roos, V. Vandenbossche, N. Meuleman, Y. Libert, D. Bron


P.14 Bendamustin shows distinct anti-tumoural responses in multiple myeloma patients that relapsed after prior bortezomib and lenalidomide treatment. A study on behalf of the MM BHS subcommittee

J. Caers, M-C. Vekemans, I. Vande Broek, P.H. Mineur, K. Beel, V. Maertens, C. Schuermans, F. Leleu, G. Vanstraelen, H. Demuynck, W. Schroyens, E. Van den Neste, G. Bries, A. Van de Velde, M. Delforge, C. Doyen


P.15 Genomic profiling of myeloma: A comparison of cytogenetics, FISH and array- CGH analysis of 95 cases at diagnosis or follow up

K. Rack, S. Vidrequin, M. Devos, L. Dargent


P.16 Expression of TMEM45A, a candidate gene of chemoresistance, in a panel of neoplastic tissues

C. Graux, L. Finet, F. George, L. D’Hondt, C. Michiels


P.17 Complete responses of the TEMPI syndrome to bortezomib

W. Schroyens, Z. Berneman, A. Gadisseur, A. Van de Velde, I. Vrelust


P.18 Concurrent B-cell chronic lymphocytic leukaemia and multiple myeloma

P. van Gaal, K. Beel, C. Denis, P. Zachée


P.19 Clonaly related monoclonal B-cell lymphocytosis and diffuse large B-cell lymphoma in a patient treated for EBV-positive Hodgkin lymphoma

C. Caron, A. De Becker, K. Fostier, M. De Waele, H. De Raeve, R. Schots, F. Trullemans


P.20 Primary Intraocular Lymphoma: a Case Report

I. Vrelust, E. Post, J. van Looveren, R. Malfait


P.21 Coincidence of renal cell carcinoma and post-transplant lymphoproliferative disorder following kidney transplantation

H. Maes, G. Verhoef, D. Kuypers, P. Schöffski, T. Tousseyn, M. Delforge, T. Devos, A. Janssens, J. Maertens, H. Schoemans, D. Dierickx


P.22 About two cases of Merkel cell carcinoma associated with chronic lymphocytic leukaemia

R. Poncin, M. Berckmans, V. Havelange, X. Poiré, I. Theate, L. Marot, R. Vanwijck, Y. Humblet, E. Danse, L. Renard, E. Van den Neste, L. Michaux, M-C. Vekemans


P.23 Heavy/light chain (HLC) and free light chain (FLC) analysis allow sensitive monitoring of multiple myeloma patients and aid detection of clonal changes

L. Dierge, L. Lutteri, D. Chauvet, D. Hastir, J.P. Chapelle, E. Cavalier


P.24 Neurolymphomatosis: 2 cases diagnosed with FDG PET

I. Bruynseels, S. Ceyssens, A. Van de Velde, W. Schroyens, A. Gadisseur, Z. Berneman, I. Vrelust


P.25 Unusual isolated intracranial relapse of multiple myeloma

M. Laruelle, M. Deldicque, L. Michaux, X. Poiré, A. Camboni, C. Grandin, M-C. Vekemans, V. Havelange


P.26 Meningioma 1 (MN1) expression: refined Risk stratification in acute myeloid leukaemia with normal cytogenetics

L. Ibrahim, S. Aref, E. Azmy


P.27 Invariant Natural Killer T cells in the 5T33 multiple myeloma model

H. Nur, K. Fostier, S. Aspeslagh, W. Renmans, E. Bertrand, X. Leleu, K. Breckpot, R. Schots, M. De Waele, E. Van Valckenborgh, E. De Bruyne, T. Facon, D. Elewaut, K. Vanderkerken, E. Menu


P.28 The IGF-1 receptor inhibitor picropodophyllin (PPP) potentiates the anti-myeloma effects of the BH3 mimetic ABT-737

L. Bieghs, E. Van Valckenborgh, E. Menu, M.T. Overgaard, M. Nyegaard, H. Johnsen, O. Larsson, H. Jernberg-Wiklund, K. Vanderkerken, E. De Bruyne


P.29 The multifaceted GATA2 gene in inherited myeloid malignancies: about a Belgian family

H. Antoine-Poirel, M. Pasquet, C. Bellané-Chantelot, S. Tavitian, N. Prade, B. Beaupain, O. la Rochelle, A. Petit, P. Rohrlich, F. Ferrand, E. Van den Neste, H.L. Phuoc Nguyen, M. Vikkula, T. Lamy, M. Ouachée, V. Mansat-de Mas, J. Corre, C. Récher, G. Plat, F. Bachelerie, J. Donadieu, E. Delabesse


P.30 Acute myeloid leukaemia infiltrating-T lymphocyte characterization

R. Rouas, M. Berehab, N. Naamane, P. Lewalle, D. Moussa-Agha, M. Merimi, P. Martiat


P.31 Study of the miRNome of childhood myelodysplastic syndrome

H.H. Helsmoortel, T. Lammens, N. Van Roy, A. Uyttebroeck, A. Ferster, Y Benoit, F. Speleman, B. De Moerloose


P.32 The generation and activation of Myeloid-Derived Suppressor Cells in Multiple Myeloma

K. De Veirman, E. De Bruyne, E. Menu, I. Van Riet, K. Vanderkerken, E. Van Valckenborgh


P.33 Hematological and molecular responses in a case of refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) treated by Lenalidomide

K. Hafraoui, J. Caers, F. Tassin, Y. Beguin


P.34 Multiple Myeloma in the era of novel agents: a single center experience

N. De Beule, K. Fostier, A. De Becker, C. Caron, F. Trullemans, R. Schots


P.35 Performance evaluation of two automated digital morphology systems, Cellavision and HemaCAM in comparison with classical microscopic analysis focusing on rare events counting and on the pre-classification efficiency of the automated systems

J. Hotton, R. Rassart, S. Swaelens, B. Broothaers, C. Cantinieaux


P.36 Management of fit older AML: major prognostic value of cytogenetic markers is confirmed whatever the age

J. Nguyen, B. Bailly, P. Sidon, J. Hotton, M. Roos, M. Maerevoet, P. Lewalle, N. Meuleman, M. Paesmans, D. Bron


P.37 Incidental diagnosis of Fanconi anemia in an adult patient with myelodysplastic syndrome

B. Poppe, E. Steel, S. Callens, K. Bonte, A. d’Heedene, F. Speleman, B. Menten, N. Van Roy


P.38 Large pericardial effusion after heterologuous stem cell transplant : about two cases

S. Ludovicy, C. Graux, A. Sonet, A. Charpentier, K. Chalabi, L. Plawny


P.39 Simultaneous diagnosis of CLL and CML in a single patient with evidence for two different cell clones

C. Bonnet, C. Menten, F. Lambert, A. Gothot, F. Baron, J. Caers, C. Herens, Y. Beguin


P.40 Hyperhaploid plasma cell myeloma: a rare case report

S. Vidrequin, K. Rack, M. Devos, T. Connerotte


P.41 Central nervous system relapse of chronic myeloid leukaemia after allogeneic hematopoietic stem cell transplantation effectively treated with dasatinib

M. Deldicque, M-C. Vekemans, V. Havelange, E. Van den Neste, L. Michaux, J.M. Scheiff, X. Poiré


ABSTRACTS ORAL PRESENTATIONS

O.1 Exome sequencing identifies mutation of the ribosome in T-ALL

K. De Keersmaecker, Z. Kalender Atak, N. Li, C. Vicente, S. Patchett, T. Girardi, V. Gianfelici, E. Geerdens, M. Porcu, I. Lahortiga, R. Luca, J. Yan, G. Hulselmans, E. Clappier, R. Vandepoel, B. Sweron, K. Jacobs, N. Mentens, I. Wlodarska, B. Cauwelier, J. Cloos, J. Soulier, A. Uyttebroeck, C. Bagni, B. Hassan, P. Vandenberghe, A. Johnson, S. Aerts, J. Cools


O.2 Nanobodies as new imaging tools in multiple myeloma: a study in the 5T2MM murine model

M. Lemaire, S. Muyldermans, T. Lahoutte, M. Menu, E. Van Valckenborgh, E. De Bruyne, N. Devoogdt, K. Vanderkerken


O.3 Donor Characteristics As Pretransplant Predictive Factors of Long-Term Outcomes After Allogeneic Peripheral Blood (PB) Stem Cell Transplantation (SCT) From HLA-Matched Related and Unrelated Donors in Patients with Hematologic Malignancies

S. Servais, R. Porcher, M. Robin, A. Xhaard, E. Masson, J. Larghero, R. Ribaud, G. Socie, R. Peffault de Latour


O.4 Combination of regulatory T cells injection with rapamycin for treatment of chronic Graft-versus-Host disease

L. Belle, M. Binsfeld, M. Hannon, J. Caers, A. Briquet, M. Menten, Y. Beguin, S. Humblet, F. Baron


O.5 In vitro generation of antigen-specific T-cells from hematopoietic progenitor cells: a new and promising immunotherapeutic strategy

S. Snauwaert, G. Goetgeluk, S. van Coppernolle, G. Verstichel, Y. Van Caeneghem, S. Vanhee, I. Velghe, J. Plum, B. Vandekerckhove, T. Kerre


O.6 Infusion of CliniMACS® (Miltenyi Biotec) enriched regulatory T-cells delays experimental xenogeneic graft-versus-host disease

M. Hannon, C. Lechanteur, J. Somja, S. Lucas, L. Belle, F. Bruck, E. Baudoux, Y. Beguin, S. Humblet-Baron, F. Baron


O.7 Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomised trial

A. Jaspers, F. Baron, E. Willems, K. Hafraoui, G. Vanstraelen, C. Bonnet, Y. Beguin


O.8 The value of asparaginase intensification for children with low and average risk acute lymphoblastic leukaemia (ALL) and non-Hodgkin lymphoma (NHL) in the EORTC-CLG Randomized Phase III Trial 58951

V. Mondelaers


X